Kopf Sebastian H, Sessions Alex L, Cowley Elise S, Reyes Carmen, Van Sambeek Lindsey, Hu Yang, Orphan Victoria J, Kato Roberta, Newman Dianne K
Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125; Howard Hughes Medical Institute, California Institute of Technology, Pasadena, CA 91125;
Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125;
Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E110-6. doi: 10.1073/pnas.1512057112. Epub 2015 Dec 29.
Effective treatment for chronic infections is undermined by a significant gap in understanding of the physiological state of pathogens at the site of infection. Chronic pulmonary infections are responsible for the morbidity and mortality of millions of immunocompromised individuals worldwide, yet drugs that are successful in laboratory culture are far less effective against pathogen populations persisting in vivo. Laboratory models, upon which preclinical development of new drugs is based, can only replicate host conditions when we understand the metabolic state of the pathogens and the degree of heterogeneity within the population. In this study, we measured the anabolic activity of the pathogen Staphylococcus aureus directly in the sputum of pediatric patients with cystic fibrosis (CF), by combining the high sensitivity of isotope ratio mass spectrometry with a heavy water labeling approach to capture the full range of in situ growth rates. Our results reveal S. aureus generation times with a median of 2.1 d, with extensive growth rate heterogeneity at the single-cell level. These growth rates are far below the detection limit of previous estimates of CF pathogen growth rates, and the rates are slowest in acutely sick patients undergoing pulmonary exacerbations; nevertheless, they are accessible to experimental replication within laboratory models. Treatment regimens that include specific antibiotics (vancomycin, piperacillin/tazobactam, tobramycin) further appear to correlate with slow growth of S. aureus on average, but follow-up longitudinal studies must be performed to determine whether this effect holds for individual patients.
对感染部位病原体生理状态的认识存在重大差距,这削弱了对慢性感染的有效治疗。慢性肺部感染导致全球数百万免疫功能低下个体发病和死亡,然而在实验室培养中有效的药物对体内持续存在的病原体群体效果要差得多。新药临床前开发所基于的实验室模型,只有在我们了解病原体的代谢状态和群体内的异质性程度时,才能复制宿主条件。在本研究中,我们通过将同位素比率质谱的高灵敏度与重水标记方法相结合,以捕捉原位生长速率的全范围,直接测量了囊性纤维化(CF)儿科患者痰液中病原体金黄色葡萄球菌的合成代谢活性。我们的结果显示,金黄色葡萄球菌的代时中位数为2.1天,在单细胞水平上生长速率存在广泛的异质性。这些生长速率远低于先前对CF病原体生长速率估计的检测限,并且在经历肺部加重的急性病患者中生长速率最慢;然而,它们在实验室模型中是可以通过实验复制的。包括特定抗生素(万古霉素、哌拉西林/他唑巴坦、妥布霉素)的治疗方案似乎进一步与金黄色葡萄球菌的平均缓慢生长相关,但必须进行后续纵向研究以确定这种效果是否适用于个体患者。